New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
12:39 EDTBAX, HALOFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
The panel voted 15-1 that the drug from Baxter (BAX) and Halozyme (HALO) has a favorable risk/benefit in treatment of primary immune deficiency disorders, according to Bloomberg.
News For BAX;HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:12 EDTBAXAmerican Academy of Orthopedic Surgeons to hold annual meeting
Subscribe for More Information
March 17, 2015
08:45 EDTHALOHalozyme management to meet with JPMorgan
Subscribe for More Information
March 16, 2015
09:15 EDTBAXCTI BioPharma shares should be bought on weakness, says Roth Capital
Subscribe for More Information
March 13, 2015
09:02 EDTBAXBaxter announces phase III trial of BAX 817 met primary endpoint
Baxter International announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa treatment for people with hemophilia A or B who develop inhibitors. The prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial met its primary endpoint of successful resolution of acute bleeding episodes at 12 hours with both on-demand treatment regimens, dosing either 3x90 g/kg or 1x270 g/kg, with an overall success rate of 92% -- 98% and 85% in each dosing group, respectively. Further, 89% of patients in the trial achieved sustained bleeding control for all acute bleeding episodes 24 hours after infusion. No patients developed inhibitors or binding antibodies to BAX 817, and none discontinued treatment due to an adverse event. One patient was hospitalized following a traumatic muscle bleed that did not respond to BAX 817. Non-serious AEs observed in the trial were generally consistent with the underlying disease or other etiology, and were all deemed to be unrelated to treatment. Full data from the trial, including additional efficacy and safety outcomes, will be presented at a medical meeting later in 2015. The company plans to initiate regulatory submissions aligned to manufacturing expansions currently underway.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use